Clinical trial NCT02421523: Strength Training in Duchenne Muscular Dystrophy
Official title: Development of a Strength Training Protocol in Duchenne Muscular Dystrophy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Duchenne Muscular Dystrophy
Keywords: Exercise
Strength training
Lead sponsor: University of Florida
Sponsor class: OTHER
Collaborators: name: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
First posted: 2015-04-20
Enrollment: 18
Sex: MALE
Minimum age (years): 7
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Duchenne muscular dystrophy (DMD) is a debilitating neuromuscular disease that causes muscle breakdown, weakness, and eventual death. Over the last 40 years parents have received little guidance on the potential of exercise as a therapeutic strategy to maintain muscle function. It is well known that high intensity exercise and eccentric contractions can result in muscle damage in dystrophic muscle, yet the absence of muscle loading will conversely result in muscle wasting. Recent research in rodent models and milder forms of muscular dystrophy supports earlier studies that resistance exercise may have beneficial effects for maintenance of muscle mass in dystrophic muscle. However, careful and systematic investigation into the safety and feasibility of resistance exercise is needed to consider its implementation in boys with DMD.

The goal of this project is to assess the safety and feasibility of a home based mild to moderate-intensity strengthening exercise program in boys with Duchenne muscular dystrophy (DMD). Evidence from milder forms of muscular dystrophy and mouse models of DMD suggests that strengthening exercise may be beneficial for these children, but this area has not been adequately explored using human subjects. The results of this study should provide information to assist in the development of scientifically based recommendations concerning optimal exercise parameters for patients with DMD.

Detailed description: The overall objective of this pilot study is to assess whether a mild to moderate-intensity strengthening exercise program can be safely implemented in boys with DMD. In Aim 1, the investigators will determine the dose response and safety of mild to moderate-intensity isometric resistance exercise in children with DMD. Twelve ambulatory boys with DMD will participate in an isometric exercise dosing protocol, in which the load is progressively increased. In this early proof of concept pilot study, two large muscle groups will be studied: the knee extensors and the knee flexors. T2 weighted magnetic resonance imaging (MRI) of the thigh muscles will be used to monitor evidence of muscle damage at each intensity level and determine a safe exercise range. Other safety measures will include a verbal pain rating scale, clinical examination, and serum creatine kinase (CK) levels. In Aim 2, the investigators will implement a pilot intervention study to examine the feasibility and safety of a 12 week in-home isometric strengthening program in children with DMD. In this study, 20 boys with DMD will be randomized to either an exercise group or a control group. Ten boys with DMD randomized to the exercise group will complete a progressive exercise program using the parameters and dose identified in Aim 1. Assessment of strength and safety will be performed at regular time intervals throughout the study. Ten boys with DMD randomized to not participate in an exercise intervention will be tested at similar time intervals and serve as controls. The data from this pilot study will serve to perform the power analysis needed to design an appropriately powered clinical intervention study.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of DMD confirmed by

  1. clinical history with features before the age of five
  2. physical examination
  3. elevated serum creatine kinase level
  4. absence of dystrophin expression, as determined by immunostain or Western blot (\<2%) and/or DNA confirmation of dystrophin mutation.
* Age 7 to 10.5 years: a lower age limit of 7 years was selected, since in our experience children younger than 7 years are likely unable to cooperate and comply with all of the exercise measures as needed. An upper age limit of 10.5 years has been set as boys with DMD tend to reach a rapid progression into a late ambulatory phase soon after this age.
* Ambulatory at the time of the first visit, defined as the ability to walk for at least 100 m without an external assistive device and able to climb four stairs.
* Currently using corticosteroids (prednisone or deflazacort) as prescribed by a physician.

Exclusion Criteria:

* Contraindication to an MR examination (e.g. aneurysm clip, severe claustrophobia, magnetic implants)
* Presence of a condition in control subjects or a secondary condition in boys with DMD that impacts muscle function or muscle metabolism (e.g. myasthenia gravis, endocrine disorder, mitochondrial disease)
* Secondary condition leading to developmental delay or impaired motor control (e.g. cerebral palsy)
* Secondary condition that impacts muscle function or muscle metabolism (e.g. myasthenia gravis, endocrine disorder, mitochondrial disease)
* Unstable medical condition (e.g. uncontrolled seizure disorder)
* Behavioral problems causing an inability to cooperate during testing

Primary outcomes:
measure: Change from baseline in T2 weighted MRI of skeletal muscle in leg for Aim 2
timeFrame: Change in baseline relative to 1 week, 6 weeks, 12 weeks
measure: Change in base line in T2 weighted MRI of skeletal muscle in leg for Aim 1
timeFrame: Change in baseline relative to 48 hours after exercise
Secondary outcomes:
measure: Change from baseline in Spectroscopic Relaxometry for Aim 2
timeFrame: Change in baseline relative to 1 week, 6 weeks, 12 weeks
measure: Change from baseline in Spectroscopic Relaxometry for Aim 1
timeFrame: Change in baseline relative to 48 hours after exercise
measure: Change from baseline in Creatine Kinase (CK) Levels for Aim 2
timeFrame: Change in baseline relative to 1 week, 3 weeks, 6 weeks, 9 weeks, 12 weeks
measure: Change from baseline in Creatine Kinase (CK) Levels for Aim 1
timeFrame: Change in baseline relative to 48 hours after exercise
measure: Change from baseline in Pain for Aim 2
timeFrame: Change in baseline relative to 1 week, 3 weeks, 6 weeks, 9 weeks, 12 weeks
measure: Change from baseline in Pain for Aim 1
timeFrame: Change in baseline relative to 48 hours after exercise
Other outcomes:
measure: Change from baseline in Strength of knee extensor and knee flexor muscles for Aim 2
timeFrame: Change in baseline relative to 6 weeks, 12 weeks
measure: Change from baseline in Stair Climbing for Aim 2
timeFrame: Change in baseline relative to 6 weeks, 12 weeks
Locations:
city: Gainesville
country: United States
facility: University of Florida
state: Florida
Study officials:
affiliation: University of Florida
name: Donovan J Lott, PhD, PT
role: PRINCIPAL_INVESTIGATOR
References: